Chart-Typ:
Zeitraum:
| Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules | SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate... ► Artikel lesen |
| Morning Market Movers: Artelo Biosciences, Onconetix, Datacentrex, Robin Energy See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
| Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments | Evaluating Potential to Preserve Muscle Mass Associated with Weight Reduction Announces Preclinical Study Initiation, Patent Filing and Publication of Independent Scientific Research SOLANA BEACH... ► Artikel lesen |
| QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen |
| QIAGEN N.V.: QIAGEN stellt neue Daten zur Wirksamkeit von QuantiFERON in der Tuberkulose-Prävention vor | Neue Studie unterstützt den Einsatz von QuantiFERON-TB Gold Plus bei immungeschwächten Personen und anderen Hochrisikogruppen in verschiedenen Settings Ergebnisse zeigen, dass der QuantiFERON-Test... ► Artikel lesen |
| QIAGEN N.V.: QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention | New study supports QuantiFERON-TB Gold Plus use in immunocompromised and other high-risk populations in various settings Findings show QuantiFERON testing is cost-effective compared with... ► Artikel lesen |
| ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen |
| ADMA Biologics, Inc.: ADMA Biologics Addresses Misleading Short-Seller Report | RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CAMP4 THERAPEUTICS CORP finden Sie auf Wallstreet Online.